���重受体激动剂的分子设计 — Worked Examples

By Editorial Desk · published 2026-07-21 · last reviewed 2026-08-01 · Guide

If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

三重受体激动剂的分子设计

该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。

retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。

三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。

Clinical Endpoints and Analytical Methods

Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.

Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.

Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.

Retatrutide at a glance

瑞他鲁肽药理机制

瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。

该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。

临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。

Related pages on this site

• Modular review
• Proven playbook
• Tracked comparison
• Comprehensive checklist
• Lightweight primer
• Sustainable primer
• Gradual guide
• Balanced handbook

Analytical Methods and Storage Practice

Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.

Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.

Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.

Further detail

The most common vehicle currently used for targeted drug delivery is the liposome. Liposomes are non-toxic, non-hemolytic, and non-immunogenic even upon repeated injections; they are biocompatible and biodegradable and can be designed to avoid clearance mechanisms (reticuloendothelial system (RES), renal clearance, chemical or enzymatic inactivation, etc.) Lipid-based, ligand-coated nanocarriers can store their payload in the hydrophobic shell or the hydrophilic interior depending on the nature of the drug/contrast agent being carried. The only problem to using liposomes in vivo is their immediate uptake and clearance by the RES system and their relatively low stability in vitro. To combat this, polyethylene glycol (PEG) can be added to the surface of the liposomes. Increasing the mole percent of PEG on the surface of the liposomes by 4-10% significantly increased circulation time in vivo from 200 to 1000 minutes. PEGylation of the liposomal nanocarrier elongates the half-life of the construct while maintaining the passive targeting mechanism that is commonly conferred to lipid-based nanocarriers. When used as a delivery system, the ability to induce instability in the construct is commonly exploited allowing the selective release of the encapsulated therapeutic agent in close proximity to the target tissue/cell in vivo. This nanocarrier system is commonly used in anti-cancer treatments as the acidity of the tumour mass caused by an over-reliance on glycolysis triggers drug release.

==== On the economic root cause ==== Stratfor believed that the act of adulterating milk and baby food in full knowledge of potentially severe sanctions, including execution, seemed like "an act of desperation". It noted that in 2008 dairy farmers became squeezed by growing costs of livestock, feed, facilities, and government-imposed price caps. Mengniu's share price had fallen 12% since October 2007 because of higher costs of raw milk (due partly to rising costs of cattle feed) and price controls—anti-inflation measures targeted at the dairy sector announced on 16 January. Milk suppliers accordingly resorted to subtler cost-cutting methods to preserve diminishing profits.

== Episode 7: Paralyzed == Joe is a 61 year old optimistic patient from Wallingford, CT. He was struck with a sudden and unexplained paralysis starting from his waist down, leaving him paraplegic. Ann is a 42 year old skeptic patient who is also from Wallingford, CT. She has intermittent paralysis where she could spend hours with the right side of her body immobile. She will then regain mobility but the paralysis always occurs again. Around the age of 59, Joe started to get pin & needles in his legs and at first he thought nothing of it until a year later he had numbness up to his knees that progressed to his waist. Eventually, the numbness turned into paralysis and Joe became a paraplegic at the age of 61. Shortly after becoming paralyzed, Joe went into a state of organ failure that doctors were able to get him out of but ever since he hasn't been able to leave the hospital. Despite visiting many hospitals such as Yale, Mayo, and Boston with no avail, he states he is still a firm believer in western medicine and is willing to try anything. Around the age of 40, Ann had a recurring pain in her chest that resembled heartburn and a month later noticed that the right side of her face looked off. When she brought this up to her primary care physician, he explained that she had full right side facial paralysis and needed to visit the emergency room as she might be having a stroke.

On 5 March, armed clashes were reported between Taliban forces and Pakistani border guards in parts of Khost, Paktia, Paktika, Kunar, Nangarhar and Kandahar provinces. The clashes were described as sporadic exchanges of fire along sections of the Afghanistan–Pakistan border. In the Spin Boldak district of Kandahar, local sources reported that four Afghan civilians had been killed in strikes by Pakistani forces. Taliban officials have not confirmed the casualties in Spin Boldak district. In Kabul, residents report hearing sounds of scattered gunfire in parts of the city. In Pakistan's Miranshah, two civilians were killed and one was injured when a missile fired from an unidentified direction struck the Governor Cottage in Cantonment area. In Mohmand district, three civilians were injured when a mortar shell fired by Afghan forces landed on a house. Pakistan claimed to have killed 12 TTP insurgents in an operation in Harnai District. The same day, Taliban-led Afghanistan's Ministry of Defense said that over the past 24 hours, 41 Pakistani soldiers had been killed and 53 others had been wounded in the clashes with Taliban forces. The Ministry added that the Taliban forces had destroyed 12 military post and shot down three reconnaissance drones of Pakistan over the past day. The Ministry also said that they have carried out airstrike on a military base in Pakistan province of Balochistan. Pakistani officials stated that they targeted 41 border outpost belonging to Afghan Taliban forces and Pakistani Taliban, resulting in heavy casualties and material losses.

Sources: en.wikipedia.org

Supporting material

Concanavalin+A at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Concanavalin+A+Receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Concanavalin A structure Archived 2008-08-20 at the Wayback Machine World of Lectin, Gateway to lectins Proteopedia 1bxh con A in complex with methyl alpha1-2 mannobioside

Paleolithic hunting and gathering people ate varying proportions of vegetables (including tubers and roots), fruit, seeds (including nuts and wild grass seeds) and insects, meat, fish, and shellfish. However, there is little direct evidence of the relative proportions of plant and animal foods. Although the term "paleolithic diet", without references to a specific timeframe or locale, is sometimes used with an implication that most humans shared a certain diet during the entire era, that is not entirely accurate. The Paleolithic was an extended period of time, during which multiple technological advances were made, many of which had impact on human dietary structure. For example, humans probably did not possess the control of fire until the Middle Paleolithic, or tools necessary to engage in extensive fishing. On the other hand, both these technologies are generally agreed to have been widely available to humans by the end of the Paleolithic (consequently, allowing humans in some regions of the planet to rely heavily on fishing and hunting). In addition, the Paleolithic involved a substantial geographical expansion of human populations. During the Lower Paleolithic, ancestors of modern humans are thought to have been constrained to Africa east of the Great Rift Valley. During the Middle and Upper Paleolithic, humans greatly expanded their area of settlement, reaching ecosystems as diverse as New Guinea and Alaska, and adapting their diets to whatever local resources were available.

The ethics of technology is an interdisciplinary subfield of ethics that analyzes technology's ethical implications and explores ways to mitigate potential negative impacts of new technologies. There is a broad range of ethical issues revolving around technology, from specific areas of focus affecting professionals working with technology to broader social, ethical, and legal issues concerning the role of technology in society and everyday life. Prominent debates have surrounded genetically modified organisms, the use of military robots, algorithmic bias, and the issue of aligning AI behavior with human values. Technology ethics encompasses several key fields: Bioethics looks at ethical issues surrounding biotechnologies and modern medicine, including cloning, human genetic engineering, and stem cell research. Computer ethics focuses on issues related to computing. Cyberethics explores Internet-related issues like intellectual property rights, privacy, and censorship. Nanoethics examines issues surrounding the alteration of matter at the atomic and molecular level in various disciplines, including computer science, engineering, and biology. And engineering ethics deals with the professional standards of engineers, including software engineers and their moral responsibilities to the public.

Sources: en.wikipedia.org

Notes from published material

H–D exchange has been used to characterize protein structures and protein–protein interactions. The exchange reaction needs to be carried out with the isolated proteins and with the complex. The exchanging regions are then compared. If a region is buried by the binding, the amides in this region may be protected in the complex and exchange slowly. However, one must bear in mind that H–D exchange cannot be used to locate binding interfaces for all protein-protein interactions. Some protein-protein interactions are driven by electrostatic forces of side chains and are unlikely to change the exchange rate of backbone amide hydrogens, particularly if the amide hydrogens are located in stable structural elements such as alpha helices. Lastly, H–D exchange can be used to monitor conformational changes in proteins as they relate to protein function. If conformation is altered as result of post-translational modification, enzyme activation, drug binding or other functional events, there will likely be a change to H/D exchange that can be detected.

Sorafenib's inhibition of UGT1A9 and UGT1A1 may increase plasma concentration of other drugs. The same goes for the CYP2B6 and CYP2C8 pathways, they are inhibited by sorafenib. Giving sorafenib in combination with rifampicin or inducers of CYP3A4 can decrease plasma concentration of sorafenib. CYP3A4 inhibitors are unlikely to affect sorafenib. Sorafenib is a competitive inhibitor of CYP2C19, CYP2D6 and CYP3A4. It inhibits P-glycoprotein, therefore it can increase the plasma concentration of drugs which are P-glycoprotein substrates. Pazopanib is metabolized in the liver by CYP3A4 enzyme. Strong CYP3A4 inhibitors, other than pazopanib, can increase the plasma concentration of pazopanib, and CYP3A4 inducers will do the opposite. Grapefruit juice is a CYP3A4 inhibitor and should be avoided when taking pazopanib. It is also a weak inhibitor of other liver enzymes, CYP2C8 and CYP2D6. Axitinib is metabolized by CYP3A4 and UGT1A1. Strong inhibitors of CYP3A4 will increase the plasma concentration of axitinib, while weak inhibitors have less effect on the plasma concentration. Strong inducers of CYP3A4 will decrease the plasma concentration of axitinib and should be avoided.

== Interactions == Enobosarm is a substrate of the cytochrome P450 enzyme CYP3A4 and the UDP-glucuronosyltransferase (UGT) enzymes UGT1A1 and UGT2B7. It shows very minimal metabolism by cytochrome P50 enzymes, with CYP3A4 merely responsible for the greatest degree of metabolism. Since enobosarm is metabolized by CYP3A4, UGT1A1, and UGT2B7, inhibitors and inducers of these enzymes can modify the metabolism and pharmacokinetics of enobosarm. The strong CYP3A4 inhibitor itraconazole was shown to have minimal to no influence on the pharmacokinetics of enobosarm, whereas the strong CYP3A4 inducer rifampin reduced enobosarm peak levels by 23%, elimination half-life by 23%, and area-under-the-curve levels by 43%. The pan-UGT inhibitor probenecid was shown to not affect peak levels of enobosarm but to increase the elimination half-life of enobosarm by 78% and to increase area-under-the-curve levels of enobosarm by 50%. Enobosarm had no effect on the pharmacokinetics of celecoxib (a CYP2C9 substrate) or rosuvastatin (a BCRP substrate). Based on the preceding findings, it was concluded that enobosarm poses low risk for clinically relevant drug interactions.

==== Dietary iron uptake ==== The absorption of dietary iron is a variable and dynamic process. The amount of iron absorbed compared to the amount ingested is typically low, but may range from 5% to as much as 35% depending on circumstances and type of iron. The efficiency with which iron is absorbed varies depending on the source. Generally, the best-absorbed forms of iron come from animal products. Absorption of dietary iron in iron salt form (as in most supplements) varies somewhat according to the body's need for iron, and is usually between 10% and 20% of iron intake. Absorption of iron from animal products, and some plant products, is in the form of heme iron, and is more efficient, allowing absorption of from 15% to 35% of intake. Heme iron in animals is from blood and heme-containing proteins in meat and mitochondria, whereas in plants, heme iron is present in mitochondria in all cells that use oxygen for respiration. Like most mineral nutrients, the majority of the iron absorbed from digested food or supplements is absorbed in the duodenum by enterocytes of the duodenal lining. These cells have special molecules that allow them to move iron into the body. To be absorbed, dietary iron can be absorbed as part of a protein such as heme protein or iron must be in its ferrous Fe2+ form. A ferric reductase enzyme on the enterocytes' brush border, duodenal cytochrome B (Dcytb), reduces ferric Fe3+ to Fe2+.

Sources: en.wikipedia.org

Frequently asked questions